Completed PHASE3 INTERVENTIONAL 2-arm NCT00602511

Thalidomide Versus Bortezomib in Melphalan Refractory Myeloma

Sponsor: Nordic Myeloma Study Group

Updated 6 times since 2017 Last updated: Feb 8, 2011 Started: Oct 31, 2007 Primary completion: Sep 30, 2010 Completion: Dec 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Multiple Myeloma and is currently completed. Nordic Myeloma Study Group leads this study, which shows 6 recorded versions since 2007 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Oct 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Nordic Myeloma Study Group

Data source: Nordic Myeloma Study Group

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aalborg, Denmark , Aarhus, Denmark , Copenhagen, Denmark , Falun, Sweden , Gothenburg, Sweden , Gävle, Sweden , Helsingborg, Sweden , Herlev, Denmark , Lidköping, Sweden , Lund, Sweden and 16 more locations